Jakafi (ruxolitinib phosphate) Tablet

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) March 2016 WARNINGS AND PRECAUTIONS Risk of Infection Hepatitis B: Hepatitis B viral load (HBV-DNA titer) increases, with or...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts